Sep 18


PRESS RELEASE BETHESDA, MD -ASHP announced today that it is incredibly disappointed in the latest court decision by the U.S District Court for the District of Columbia which will exclude all medicines with an orphan designation from the 340B Medication Pricing Program for rural and malignancy hospitals. In an 14 decision October, the courtroom struck down an interpretive guideline by medical Resources and Solutions Administration that allowed rural hospitals and additional facilities newly qualified to receive 340B discounts to utilize the program to get orphan drugs when the product will not be utilized for the orphan indication Click to read more . This ruling will limit access to critical medicines for the sickest sufferers in our healthcare program, said Kasey K.

The documents help programs interpret the typical, understand the linked competency areas, goals, and objectives, and assess their degree of compliance. The interpretations also describe the methods accreditation surveyors will use to evaluate compliance, including overview of documentation, discussions with this program director, preceptors, and citizens, and observations gathered during a tour of facilities. The release of the guidance files is along with a series of easily accessible online teaching webinars. These webinars, entitled Residency Program Style and Conduct Documented Webinar Series, review accreditation requirements for the new standards with a primary focus on Standard 3—the conduct and design of PGY1 residency programs.